Results 161 to 170 of about 22,102,546 (289)

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Phloroglucinol inhibits human ureteral contractions via activation of cAMP‐PKA pathway

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Phloroglucinol is used to treat renal colic, especially when non‐steroidal anti‐inflammatory drugs are contraindicated. This study aimed to clarify its mechanism by examining effects on human ureteral contractility and underlying signalling pathways. Experimental Approach Urinary levels of neurokinin A (NKA), substance P
Hanwen Liu   +12 more
wiley   +1 more source

Neuropeptid Y [PDF]

open access: yes, 2018
R. Tauber, F. H. Perschel
openaire   +1 more source

Neuropeptide Y Receptor Binding Profiles of Endogenous Ligands in the Presence and Absence of Sodium: A Panoramic View. [PDF]

open access: yesACS Pharmacol Transl Sci
Gattor AO   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy